Wojciech Jurczak

Wojciech Jurczak is a consultant and professor of hematology at Memorial Maria Sklodowska Curie National Research Institute of Oncology, in Cracow, Poland, where he is in charge of the Lymphoid Malignancy Dpt. Previously, since 1992, he led the lymphoma team at Jagiellonian University. Most of his research activity in the first 15 years were related to development of monoclonal antibodies in B cell lymphomas, and practical aspects of stem cell transplantation. At that time radio-immunotherapy with Y90 labeled Ibritumomab tiuxetan was investigated, especially as consolidation of MCL and DLBCL patients, either in mono-therapy, or as an element of Z-BEAM conditioned ASCT. In the last decade, establishing Pratia-MCM, a private research facility, allowed the lymphoma team to take part in over 100 clinical trials, including phase I protocols. Wojciech Jurczak is a co-author of publications leading to registration of Ibrutinib, Acalabrutinib, Idelalisib, Belinostat, Lenalidomide, Venetoclax and Rituximab biosimilars. At present his research is focused on developing II generation BTK inhibitors, antiPD1 molecules, DARTs and BITEs. In collaboration with ICOS he initiates investigator sponsored studies assessing cardiotoxicity in lymphoma patients and methods of primary cardioprotection. Being a member of ASH, EHA, PLRG and EMCLN, his papers were published in NEJM, Blood, JCO, The Lancet, Lancet Oncology, Annals of Oncology etc.